Treatments

Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease

Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease

By

This is the first study to have validated a metformin dose adjustment as a function of the estimated glomerular filtration rate in patients with type 2 diabetes and chronic kidney disease.

Antithyroid Drugs Increase Risk of Congenital Malformations

Antithyroid Drugs Increase Risk of Congenital Malformations

Exposure to anti-thyroid drugs during the first trimester of pregnancy is associated with increased risk of congenital malformations.

NovoFine 30G 8mm Pen Needle Will Be Discontinued

NovoFine 30G 8mm Pen Needle Will Be Discontinued

By

Novo Nordisk has announced that the NovoFine 30G 8mm pen needle will be discontinued on or before April 30, 2018.

First trimester exposure to antithyroid drugs associated with increased risk of birth defects

First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.

Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D

Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D

By

Patients identified with increased insulin resistance following intra-articular corticosteroid injection or any systemic steroid treatment might need a special emphasis regarding management and followup.

Preoperative Liraglutide May Stabilize Postoperative Plasma Glucose in T2D

Preoperative Liraglutide May Stabilize Postoperative Plasma Glucose in T2D

For patients with type 2 diabetes undergoing non-cardiac surgery, premedication with liraglutide is associated with reduced median plasma glucose 1 hour postoperatively.

FDA Accepts New Drug Application for Treatment of Rare Neuroendocrine Tumors

FDA Accepts New Drug Application for Treatment of Rare Neuroendocrine Tumors

By

The Food and Drug Administration has accepted the New Drug Application for Azedra for the treatment of malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma.

FDA Approves 3 New Drugs for T2D in Adults

FDA Approves 3 New Drugs for T2D in Adults

By

Steglatro is indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and Steglujan is indicated as adjunct when treatment with both ertugliflozin and sitagliptin are appropriate.

Levothyroxine in Pregnancy Did Not Affect Neonatal Admission Rates

Levothyroxine in Pregnancy Did Not Affect Neonatal Admission Rates

By

Study aimed to evaluate the benefits of levothytoxine treatment on pregnancy outcomes in subclinical hypothyroid pregnant women who are negative for thyroid peroxidase antibody.

Optimal Dose of Linagliptin Determined for Pediatric T2D

Optimal Dose of Linagliptin Determined for Pediatric T2D

By

Study sought to determine the optimal dosing of linagliptin for the treatment of children with type 2 diabetes.

Glycemic Control Variations With Biphasic Insulin Aspart vs Basal-Bolus Therapy

Glycemic Control Variations With Biphasic Insulin Aspart vs Basal-Bolus Therapy

By

A randomized controlled trial evaluated whether treatment intensification with biphasic insulin aspart 30 improved glycemic control in patients with type 2 diabetes.

New Report Standardizes Clinically Meaningful T1D Outcomes Beyond HbA1c Testing

New Report Standardizes Clinically Meaningful T1D Outcomes Beyond HbA1c Testing

By

Representatives from multiple associations and societies have issued a new report standardizing clinically meaningful outcome measures for type 1 diabetes, beyond using HbA1c testing.

More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes

More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes

By

Patients with diabetes taking saxagliptin, sitagliptin, second-generation sulfonylureas, pioglitazone, and long-acting insulin were assessed for the risk of acute myocardial infarction.

FDA: Semaglutide Approval for Adults With T2D

FDA: Semaglutide Approval for Adults With T2D

By

Semaglutide, a once-weekly GLP-1 receptor agonist, demonstrated clinically significant reductions in HbA1c among adults with type 2 diabetes.

Glycemic Control Improved With Addition of Sotagliflozin to Insulin

Glycemic Control Improved With Addition of Sotagliflozin to Insulin

By

Study assessed the effects of sotagliflozin vs placebo with respect to glycemic control and the occurrence of severe hypoglycemia and diabetic ketoacidosis among adults with type 1 diabetes.

No Difference in Cardiovascular Outcomes With Exenatide vs Placebo in T2D

No Difference in Cardiovascular Outcomes With Exenatide vs Placebo in T2D

By

Once-weekly administration of extended-release exenatide in patients with T2D at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk.

Empagliflozin Reduces CVD Risk in Patients With T2D and PAD

Empagliflozin Reduces CVD Risk in Patients With T2D and PAD

By

Empagliflozin lowered the risk of cardiovascular death vs placebo when added to standard of care in adults with both type 2 diabetes and peripheral artery disease.

Adjunctive Dapagliflozin Improves Glycemic Control in T1D

Adjunctive Dapagliflozin Improves Glycemic Control in T1D

By

Dapagliflozin improves glycemic control in patients with inadequately controlled type 1 diabetes currently taking insulin.

Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes

Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes

By

A study of the once-weekly investigational dipeptidyl peptidase-4 omarigliptin reported a clinically meaningful reduction in glycated hemoglobin that was maintained throughout the study.

Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients

Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients

By

The association between statin use and diabetes risk in a cohort of overweight and obese patients was examined.

Short-Term Probiotics Increase Weight Loss in Overweight, Obesity

Short-Term Probiotics Increase Weight Loss in Overweight, Obesity

Probiotic supplementation resulted in a significant reduction in body weight, BMI, and fat percentage in people with overweight or obesity.

Insulin Glargine Associated With Breast Cancer Risk in T2D

Insulin Glargine Associated With Breast Cancer Risk in T2D

By

Researchers assessed whether long-term use of long-acting insulin analogs, compared with the use of neutral protamine Hagedorn insulin, is associated with an increased risk of breast cancer in women with T2D.

FDA Approves Drug for Mucopolysaccharidosis Type VII

FDA Approves Drug for Mucopolysaccharidosis Type VII

By

Mepsevii replaces beta-glucuronidase, the deficiency of which causes an abnormal buildup of toxic materials in the body's cells.

Dementia Risk Reduced With Metformin in Veterans With T2D

Dementia Risk Reduced With Metformin in Veterans With T2D

Metformin is linked to a lower dementia risk compared to sulfonylureas among veterans with type 2 diabetes.

Patient Nonadherence Often Misidentified as Diabetes Treatment Failure

Patient Nonadherence Often Misidentified as Diabetes Treatment Failure

Second-line treatments are often initiated without first using first-line therapies.

DPP4-i Plus α-Glucosidase Inhibitor Reduces HbA1c in T2D

DPP4-i Plus α-Glucosidase Inhibitor Reduces HbA1c in T2D

People with T2D experienced greater HbA1c reductions with the addition of a DPP4 inhibitor vs placebo.

FDA Approves Exenatide Extended-Release Injection for T2D

FDA Approves Exenatide Extended-Release Injection for T2D

By

The new formulation of Bydureon BCise allows for once-weekly administration with an autoinjector pen.

Improved Outcomes in Prediabetes, T2D With Liraglutide

Improved Outcomes in Prediabetes, T2D With Liraglutide

The efficacy of liraglutide therapy was examined in metformin-treated subjects with obesity.

High-Dose Beta-Blockers More Effective in Chronic Heart Failure, Diabetes

High-Dose Beta-Blockers More Effective in Chronic Heart Failure, Diabetes

By

Greater prognostic advantages were associated with high-dose beta blockers in chronic heart failure with diabetes.

Treating Endometriosis-Related Pain With Ethinylestradiol/Drospirenone Regimen

Treating Endometriosis-Related Pain With Ethinylestradiol/Drospirenone Regimen

Researchers examined the efficacy of FlexibleMIB (ethinylestradiol/drospirenone) vs placebo as therapy for endometriosis-related pain.

Sign Up for Free e-Newsletters

CME Focus